Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies

References

• Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J. Clin. Gastroenterol.14(4), 318–327 (1992).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Cohen RD, Becker RV 3rd, Larson LR, Vreeland mg. Advances in the management of Crohn’s disease: economic and clinical potential of infliximab. Clin Ther,20(5), 1009–1028 (1998).
   Google Scholar
• Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J. Clin. Gastroenterol.14(4), 309–317 (1992).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Vreeland mg, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am. J. Gastroenterol.95(8), 1955–1960 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen RD, Larson LR, Roth JR, Becker RV, Mummert MM. The cost of hospitalizations in Crohn’s disease. Am. J. Gastroenterol.95(2), 524–530 (2000).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Papineau N, Zajaczkowski J et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am. J. Gastroenterol.95(3), 677–683 (2000).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am. J. Gastroenterol.101(1), 110–118 (2006).
   PubMedGoogle Scholar
• Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut53(10), 1471–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand. J. Gastroenterol.32(11), 1134–1139 (1997).
   PubMed Web of Science ®Google Scholar
• Blomqvist P, Feltelius N, Lofberg R, Ekbom A. A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment. Pharmacol. Ther.15(4), 475–481. (2001).
   PubMedGoogle Scholar
• Silverstein MD, Loftus EV, Sandborn WJ et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology117(1), 49–57 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen RD. The economics of inflammatory bowel disease. In: Inflammatory bowel disease: diagnosis and therapeutics. Cohen RD (Ed.), Humana Press, NJ, USA 307–326 (2003).
   Google Scholar
• Binder V. Epidemiology, course and socio-economic influence of inflammatory bowel disease. Schweiz. Med. Wochenschr.118(20), 738–742 (1988).
   PubMedGoogle Scholar
• Binder V. Prognosis and quality of life in patients with ulcerative colitis and Crohn’s disease. Int. Disabil. Stud.10(4), 172–174 (1988).
   PubMedGoogle Scholar
• Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn’s disease–based on results from a regional patient group from the county of Copenhagen. Gut26(2), 146–150. (1985).
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology103(3), 954–960 (1992).
   PubMed Web of Science ®Google Scholar
• Sonnenberg A. Geographic variation in the incidence of and mortality from inflammatory bowel disease. Dis. Colon Rectum29(12), 854–861 (1986).
   PubMed Web of Science ®Google Scholar
• Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut31(9), 1037–1040 (1990).
   PubMed Web of Science ®Google Scholar
• Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut35(5), 665–668 (1994).
   PubMed Web of Science ®Google Scholar
• Sonnenberg A. Disability from inflammatory bowel disease among employees in West Germany. Gut30(3), 367–370 (1989).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549. (2002).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn’s disease. J. Clin. Gastroenterol.39(5), 390–395 (2005).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol.99(1), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Feagan B, Yan S, Bala M et al. High rates of disability and unemployment in patients with fistulizing Crohn’s disease. Am. J. Gastroenterol.97(9), S264 (abstract) (2002).
   Google Scholar
• Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J. Clin. Gastroenterol.35(2), 151–156 (2002).
   PubMed Web of Science ®Google Scholar
• Harrison J, Rubenstein J, Leff A, Cohen R. A controlled trial of the impact of infliximab upon health care utilization, costs, and charges in patients with Crohn’s disease. Gastroenterology124(4), (2003) (Abstract A521).
   PubMedGoogle Scholar
• Jewell DP, Satsangi J, Lobo A et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur. J. Gastroenterol. Hepatol.17(10), 1047–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology128(4), 862–869 (2005).
   PubMed Web of Science ®Google Scholar
• Bodger K. Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics23(9), 875–888 (2005).
   PubMedGoogle Scholar
• Clark W, Raftery J, Song F et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol. Assess.7(3), 1–78 (2003).
   PubMedGoogle Scholar
• Arseneau KO, Cohn SM, Cominelli F, Connors AF, Jr. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology120(7), 1640–1656. (2001).
   PubMed Web of Science ®Google Scholar
• Cohen RD. Cost utility of initial medical management for Crohn’s disease perianal fistula. Gastroenterology122(4), 1187–1188; discussion 1188–1190. (2002).
   PubMedGoogle Scholar
• Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost–utility analysis. Int. J. Technol. Assess. Health Care20(3), 274–279 (2004).
   PubMed Web of Science ®Google Scholar
• Hilsden R. Funding the new biologics–what can we learn from infliximab? The CCOHTA report: a gastroenterologist’s viewpoint. Can. J. Gastroenterol.16(12), 865–868 (2002).
   PubMedGoogle Scholar
• Mitton CR. Funding the new biologics – a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn’s disease. Can. J. Gastroenterol.16(12), 873–876 (2002).
   PubMedGoogle Scholar
• Lewis S. Funding the new biologics – public policy issues in drug formulary decision making. Can. J. Gastroenterol.16(12), 869–872 (2002).
   PubMedGoogle Scholar
• Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured setting. Am. J. Ther.13(6), 502–506 (2006).
   PubMedGoogle Scholar
• Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Impact of surgery for Crohn’s disease on health-related quality of life. Am. J. Gastroenterol.95(1), 177–182 (2000).
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology106(2), 287–296 (1994).
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Leserman J, Patrick DL. Ulcerative colitis and Crohn’s disease health status scales for research and clinical practice. J. Clin. Gastroenterol.15(2), 104–112 (1992).
   PubMedGoogle Scholar
• Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig. Dis. Sci.34(9), 1379–1386 (1989).
   PubMed Web of Science ®Google Scholar
• Hjortswang H, Strom M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am. J. Gastroenterol.93(11), 2203–2211 (1998).
   PubMed Web of Science ®Google Scholar
• Moser G, Tillinger W, Sachs G et al. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol.7(9), 853–858 (1995).
   PubMed Web of Science ®Google Scholar
• Meyers S, Walfish JS, Sachar DB et al. Quality of life after surgery for Crohn’s disease: a psychosocial survey. Gastroenterology78(1), 1–6 (1980).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol.98(10), 2232–2238 (2003).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn’s disease. Inflamm. Bowel Dis.8(4), 237–243 (2002).
   PubMed Web of Science ®Google Scholar
• van Balkom BP, Schoon EJ, Stockbrugger RW et al. Effects of anti-tumour necrosis factor-α therapy on the quality of life in Crohn’s disease. Aliment. Pharmacol. Ther.16(6), 1101–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Cadahia V, Garcia-Carbonero A, Vivas S et al. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn’s disease in clinical practice. Rev. Esp. Enferm. Dig.96(6), 369–374 (2004).
   PubMedGoogle Scholar
• Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med.352(24), 2499–2507 (2005).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Radford-Smith G et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut53(10), 1485–1493 (2004).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Feagan BG. Review article: economic issues in Crohn’s disease–assessing the effects of new treatments on health-related quality of life. Aliment. Pharmacol. Ther.13(Suppl. 4), 29–38 (1999).
   PubMedGoogle Scholar
• Blumenstein K, Johannesson M. Economic evaluation in healthcare: a brief history and future directions.Pharmacoeconomics10(2), 114–122 (1996)
   PubMedGoogle Scholar
• Marshall JK, Blackhouse G, Goeree R et al. Clinical and economic assessment: infliximab for the treatment of Crohn’s disease. Canadian Coordinating Office for Health Technology Assessment. Technology Overview No. 8 (2002).
   Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics13(4), 397–409 (1998).
   PubMed Web of Science ®Google Scholar
• Gregor JC, McDonald JWD, Klar N et al. An evaluation of utility measurement in Crohn’s disease. Inflamm. Bowel Dis.3, 265–276 (1997).
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence. Guidance on the use of orlistat for the treatment of obesity in adults. NICE technology appraisal guidance. 22, (2000).
   Google Scholar